Top Stories
Lilly Launches Foundayo, Kicking Off Head-to-Head Oral Obesity Showdown With Novo
Eli Lilly announced the formal commercial launch of oral obesity drug Foundayo (orforglipron), priced at $149/mo for self-pay patients at the starting dose—matching Novo's oral Wegovy pricing. Lilly had pre-stocked $1.5 billion of inventory ahead of the FDA approval on April 2. The competitive dynamics are materially different from the injectable race: in Phase 3 trials, oral Wegovy achieved 16.6% weight loss at 72 weeks versus Foundayo's 11.2%, though no direct head-to-head study exists. However, Foundayo carries a meaningful convenience advantage—it can be taken with or without food, while oral Wegovy requires a 30-minute empty-stomach fast. Foundayo is also a small molecule rather than a peptide, offering manufacturing scalability advantages. Amazon Pharmacy is offering same-day delivery in nearly 3,000 cities. Both companies are counting on Medicare GLP-1 coverage expansion effective July 1, with co-pays potentially as low as $50/month. Lilly, which has manufacturing and convenience advantages with its small-molecule oral formulation Novo, whose oral Wegovy faces peptide manufacturing complexity and fasting administration requirements that may limit real-world adherence The key question: can Novo's early lead and superior efficacy data hold against Lilly's convenience edge and injectable-market brand momentum? A Truveta report found 36% of early oral Wegovy patients were GLP-1 naïve, suggesting pills are indeed expanding the market beyond injectable switchers.
Novo Launches Wegovy HD 7.2 mg at $399/Month, Underpricing Lilly's Top Zepbound Doses by ~40%
Novo Nordisk made its higher-dose Wegovy HD (semaglutide 7.2 mg) injection available nationwide on April 7, priced at $399/mo for cash-pay patients—approximately 40% below what Lilly charges for the top three doses of Zepbound. The dose was approved in March under the FDA Commissioner's National Priority Review Voucher program. In the Phase 3b STEP UP trial, the 7.2 mg dose delivered 21% average body weight loss (efficacy estimand) at 72 weeks, compared with 18% on the existing 2.4 mg maximum dose. Commercially insured patients may pay as little as $25/month. Wegovy HD is available through 70,000+ U.S. pharmacies, NovoCare Pharmacy, and select telehealth providers. Novo Nordisk, which now offers the highest-efficacy injectable GLP-1 for obesity on the market and has undercut Lilly on price Lilly, whose Zepbound faces pricing pressure from below while its oral launch absorbs management attention The strategic calculus is clear: Novo is using aggressive pricing on its highest-efficacy injectable to stem market share losses while simultaneously building the oral Wegovy franchise. BMO analysts acknowledged the higher dose as a step forward but cautioned Novo still faces an uphill battle regaining injectable share from Lilly.
Gan & Lee Signs Third Overseas Out-Licensing Deal for Bi-Weekly GLP-1RA Bofanglutide With South Korea's JW Pharmaceutical
China's Gan & Lee Pharmaceuticals signed an exclusive licensing agreement granting JW Pharmaceutical (South Korea) rights to develop and commercialize bofanglutide injection in South Korea. The deal is worth up to $81.1 M including a $5 million upfront payment and $76.1 million in milestone payments tied to clinical, regulatory, and commercial targets, plus tiered royalties. Bofanglutide (GZR18) is a bi-weekly administered GLP-1RA—potentially the first commercially available every-two-week GLP-1 agent—targeting obesity, T2DM, and metabolic diseases. In Phase 2b results for obesity, bi-weekly dosing over 30 weeks produced average weight loss of 17.29%. The program is now in Phase 3 in China with JW Pharmaceutical planning South Korean Phase 3 trials in H2 2026. This is Gan & Lee's third overseas out-licensing deal for bofanglutide, following partnerships in Latin America and India. Gan & Lee, which is building a global commercial network for a differentiated dosing schedule without competing directly against Novo or Lilly's weekly/daily formats Second-tier GLP-1 developers without a dosing differentiation story face increasingly crowded positioning JW Pharmaceutical shares rose 7.2% on the announcement.
Competitive Landscape
With both pills now commercially available, the oral GLP-1 market crystallizes around a clear trade-off. Novo's oral Wegovy offers superior weight loss (16.6% vs. 11.2%) but requires fasting administration and peptide-class manufacturing constraints. Lilly's Foundayo offers food-agnostic dosing and small-molecule manufacturing economics but lower efficacy. Both are priced identically at $149/month for self-pay starters. The overall GLP-1 market, which gains new patient inflows as pills lower the barrier to entry—36% of early oral Wegovy patients were treatment-naïve Compounding pharmacies, whose value proposition weakens as branded oral options at $149/month approach compounded GLP-1 price points
| Feature | Foundayo (Lilly) | Oral Wegovy (Novo) |
|---|---|---|
| Weight Loss (Phase 3) | 11.2% at 36 wks | 16.6% at 72 wks |
| Fasting Required | No | Yes (30 min) |
| Molecule Type | Small molecule | Peptide |
| Self-Pay Start Price | $149/mo | $149/mo |
| US Launch Date | April 10, 2026 | January 2026 |
Novo is executing a coherent two-track pricing strategy. On injectables, Wegovy HD at $399/month undercuts Lilly's top Zepbound doses by ~40%, directly targeting the high-value patient segment that drives the most revenue per script. On orals, Novo matches Lilly dollar-for-dollar at $149/month, competing on efficacy rather than price. Combined with Novo's planned subscription pricing and the July 1 Medicare coverage expansion, this strategy prioritizes volume recapture over per-unit revenue. Patients and payers, who benefit from intensifying price competition across all GLP-1 formats Novo's near-term margins, as the company's 2026 guidance already projects a 5–13% adjusted sales decline at constant exchange rates
| Format | Novo Price | Lilly Price | Novo Advantage |
|---|---|---|---|
| Oral (starter) | $149/mo | $149/mo | Efficacy edge |
| Injectable HD | $399/mo | ~$650+/mo (top Zepbound) | ~40% cheaper |
| Insured co-pay | As low as $25 | As low as $25 | Parity |
Gan & Lee's bofanglutide offers a strategic lesson for GLP-1 developers outside the Novo-Lilly duopoly: dosing frequency differentiation may be the only viable path to market entry. With once-weekly injectables and daily orals locked up by the two incumbents, bi-weekly administration (and potentially monthly depots) represents a distinct positioning. Bofanglutide's Phase 2b data showing 17.29% weight loss in 30 weeks is competitive with early Wegovy data at comparable timepoints. The three-market out-licensing strategy (Latin America, India, South Korea) builds a revenue base outside the U.S./EU duopoly battleground. Regional pharma partners like JW Pharmaceutical, which gain GLP-1 portfolio access without competing directly in the U.S. price war Me-too weekly GLP-1 developers without differentiated dosing or mechanism, facing near-impossible commercial paths against Novo and Lilly
Forward Looking
- Watch Foundayo prescription volume in the first two weeks post-launch. Oral Wegovy hit 3,000+ patients in its launch week and surged 500% in week two. If Foundayo matches or exceeds that pace despite Novo's three-month head start, it signals Lilly's convenience advantage and injectable brand halo are translating to oral.
- Novo reports Q1 2026 earnings in May, which will include oral Wegovy revenue for the first time. GlobalData projects the overall Wegovy portfolio growing from $13.5 billion in 2026 to $18.9 billion by 2031, with the pill contributing $2.76 billion. Q1 numbers will be the first hard test of those forecasts.
- Medicare GLP-1 coverage expands July 1 following the Novo/Lilly pricing deal with the Trump administration. With co-pays potentially as low as $50/month, this is the single largest near-term volume catalyst for both companies. Monitor formulary placement decisions at the top five Medicare Part D plans in Q2.
- Track Gan & Lee's bofanglutide Phase 3 progress in China and JW Pharmaceutical's planned South Korean Phase 3 initiation in H2 2026. If Phase 3 confirms the 17.29% weight-loss signal from Phase 2b with bi-weekly dosing, the asset becomes a credible licensing target for ex-U.S. markets and potentially a differentiated U.S. filing candidate.
- Injectable Wegovy scripts have been trending downward as oral Wegovy gains share—falling 6.5% this week per BMO data. Watch for the net revenue impact: if oral scripts largely cannibalize injectables rather than expanding the patient pool, Novo's subscription pricing strategy becomes even more critical to maintaining franchise revenue.